
Kogieleum L Naidoo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6642197/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal of Medicine, 2010, 362, 697-706.	13.9	608
2	Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal of Medicine, 2011, 365, 1492-1501.	13.9	451
3	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	5.7	353
4	Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. Journal of Antimicrobial Chemotherapy, 2018, 73, 1138-1151.	1.3	219
5	The Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy Initiation in Patients With Tuberculosis: Findings From the SAPiT Trial. Annals of Internal Medicine, 2012, 157, 313.	2.0	101
6	Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 209, 500-509.	1.9	99
7	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	1.6	90
8	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	4.6	84
9	Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV,the, 2018, 5, e400-e404.	2.1	75
10	Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet, The, 2016, 387, 1198-1209.	6.3	70
11	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV,the, 2020, 7, e229-e237.	2.1	66
12	HIV, Tuberculosis, and Noncommunicable Diseases. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S87-S95.	0.9	63
13	Long-term adherence to antiretroviral therapy in a South African adult patient cohort: a retrospective study. BMC Infectious Diseases, 2019, 19, 775.	1.3	54
14	A Review of Moxifloxacin for the Treatment of Drug‧usceptible Tuberculosis. Journal of Clinical Pharmacology, 2017, 57, 1369-1386.	1.0	52
15	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	3.2	51
16	The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. European Journal of Clinical Pharmacology, 2012, 68, 689-695.	0.8	50
17	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	1.5	46
18	A Qualitative Study of Patient Motivation to Adhere to Combination Antiretroviral Therapy in South Africa. AIDS Patient Care and STDs, 2015, 29, 299-306.	1.1	39

Kogieleum L Naidoo

#	Article	IF	CITATIONS
19	Implementation of Adolescent-Friendly Voluntary Medical Male Circumcision Using a School Based Recruitment Program in Rural KwaZulu-Natal, South Africa. PLoS ONE, 2014, 9, e96468.	1.1	38
20	Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. Journal of Antimicrobial Chemotherapy, 2017, 72, 1441-1449.	1.3	38
21	When to start antiretroviral therapy during tuberculosis treatment?. Current Opinion in Infectious Diseases, 2013, 26, 35-42.	1.3	37
22	Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. Aids, 2017, 31, 2217-2225.	1.0	37
23	Determinants of Optimal Adherence Over Time to Antiretroviral Therapy Amongst HIV Positive Adults in South Africa: A Longitudinal Study. AIDS and Behavior, 2011, 15, 1465-1474.	1.4	35
24	Low rifampicin concentrations in tuberculosis patients with HIV infection. Journal of Infection in Developing Countries, 2014, 8, 987-993.	0.5	35
25	Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa. BMJ Global Health, 2019, 4, e001097.	2.0	34
26	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	2.9	34
27	Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacogenomics, 2019, 20, 225-240.	0.6	32
28	Metformin as Host-Directed Therapy for TB Treatment: Scoping Review. Frontiers in Microbiology, 2020, 11, 435.	1.5	30
29	Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. International Journal of Tuberculosis and Lung Disease, 2014, 18, 147-154.	0.6	29
30	Mortality and treatment response amongst HIV-infected patients 50Âyears and older accessing antiretroviral services in South Africa. BMC Infectious Diseases, 2018, 18, 168.	1.3	28
31	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	0.8	28
32	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infectious Diseases, The, 2022, 22, 1042-1051.	4.6	28
33	Factors affecting first-month adherence to antiretroviral therapy amongHIV-positive adults in South Africa. African Journal of AIDS Research, 2010, 9, 117-124.	0.3	25
34	Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol. Implementation Science, 2017, 12, 129.	2.5	25
35	A retrospective cohort study of body mass index and survival in HIV infected patients with and without TB co-infection. Infectious Diseases of Poverty, 2018, 7, 35.	1.5	25
36	Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out. Archivos De Bronconeumologia, 2020, 56, 446-454.	0.4	24

#	Article	IF	CITATIONS
37	Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa. Clinical Infectious Diseases, 2017, 65, 819-826.	2.9	23
38	Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field. Frontiers in Microbiology, 2022, 13, 775030.	1.5	22
39	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. AIDS Research and Human Retroviruses, 2019, 35, 129-138.	0.5	21
40	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study. BMJ Open, 2017, 7, e017507.	0.8	19
41	Individualised Motivational Counselling to Enhance Adherence to Antiretroviral Therapy is not Superior to Didactic Counselling in South African Patients: Findings of the CAPRISA 058 Randomised Controlled Trial. AIDS and Behavior, 2015, 19, 145-156.	1.4	18
42	Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. International Journal of Tuberculosis and Lung Disease, 2017, 21, 537-543.	0.6	17
43	Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opinion on Drug Safety, 2011, 10, 559-574.	1.0	16
44	Changes to Antiretroviral Drug Regimens during Integrated TB–HIV Treatment: Results of the Sapit Trial. Antiviral Therapy, 2014, 19, 161-169.	0.6	16
45	Interleukin 1-Beta (IL-1β) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 213-220.	0.9	16
46	Effect of genetic variation in <i>UGT1A</i> and <i>ABCB1</i> on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018, 19, 17-29.	0.6	16
47	Whole genome sequencing for the management of drug-resistant TB in low income high TB burden settings: Challenges and implications. Tuberculosis, 2017, 107, 137-143.	0.8	15
48	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Communications Medicine, 2022, 2, .	1.9	15
49	Aetiology, Clinical Presentation, and Outcome of Meningitis in Patients Coinfected with Human Immunodeficiency Virus and Tuberculosis. AIDS Research and Treatment, 2011, 2011, 1-6.	0.3	14
50	HIV-Associated Tuberculosis. Clinical and Developmental Immunology, 2011, 2011, 1-8.	3.3	14
51	High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 438-446.	0.9	14
52	Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e1-e7.	0.9	14
53	Precision medicine in resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug. Journal of Infection, 2019, 78, 261-268.	1.7	13
54	High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial. Clinical Infectious Diseases, 2020, 70, 2675-2682.	2.9	13

Kogieleum L Naidoo

#	Article	IF	CITATIONS
55	High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa. BMC Infectious Diseases, 2020, 20, 847.	1.3	13
56	High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. PLoS ONE, 2017, 12, e0184124.	1.1	13
57	Detecting <i>Mycobacterium tuberculosis</i> using the loop-mediated isothermal amplification test in South Africa. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1154-1160.	0.6	12
58	TB epidemiology: where are the young women? Know your tuberculosis epidemic, know your response. BMC Public Health, 2018, 18, 417.	1.2	12
59	A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial. Clinical Infectious Diseases, 2020, 70, 90-98.	2.9	12
60	Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out. Archivos De Bronconeumologia, 2020, 56, 446-454.	0.4	12
61	Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Frontiers in Immunology, 2021, 12, 676980.	2.2	12
62	Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?. Lancet Infectious Diseases, The, 2022, 22, e121-e127.	4.6	12
63	Effects of a Reduced Dose of Stavudine on the Incidence and Severity of Peripheral Neuropathy in HIV-Infected Adults in South Africa. Antiviral Therapy, 2012, 17, 737-743.	0.6	11
64	A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 71, 2645-2654.	2.9	11
65	Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa. Frontiers in Immunology, 2021, 12, 641065.	2.2	11
66	Changes to antiretroviral drug regimens during integrated TB–HIV treatment: results of the SAPiT trial. Antiviral Therapy, 2014, 19, 161-169.	0.6	11
67	Efavirenz Dosing: Influence of Drug Metabolizing Enzyme Polymorphisms and Concurrent Tuberculosis Treatment. Antiviral Therapy, 2015, 20, 297-306.	0.6	10
68	Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 576-584.	0.9	10
69	Quality of TB care among people living with HIV: Gaps and solutions. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 17, 100122.	0.6	10
70	Tuberculosis Elimination in the Era of Coronavirus Disease 2019 (COVID-19): A Moving Target. Clinical Infectious Diseases, 2022, 74, 509-510.	2.9	10
71	Primary HIV-1 Drug Resistant Minority Variants. AIDS Reviews, 2017, 19, 89-96.	0.5	10
72	Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal. Infection and Drug Resistance, 2018, Volume 11, 1413-1421.	1.1	9

#	Article	IF	CITATIONS
73	Immunoscreening of the M. tuberculosis F15/LAM4/KZN secretome library against TB patients′ sera identifies unique active- and latent-TB specific biomarkers. Tuberculosis, 2019, 115, 161-170.	0.8	9
74	Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: Impact on bedside clinical decision making. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020, 20, 100176.	0.6	9
75	Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals. Journal of Antimicrobial Chemotherapy, 2020, 75, 3319-3326.	1.3	9
76	The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV–Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 430-436.	0.9	8
77	Insights into Recurrent Tuberculosis: Relapse Versus Reinfection and Related Risk Factors. , 0, , .		8
78	Joint modelling of longitudinal and time-to-event data: an illustration using CD4 count and mortality in a cohort of patients initiated on antiretroviral therapy. BMC Infectious Diseases, 2020, 20, 256.	1.3	8
79	A Mycobacterium tuberculosis Specific IgG3 Signature of Recurrent Tuberculosis. Frontiers in Immunology, 2021, 12, 729186.	2.2	8
80	Assessing Adherence to Antiretroviral Therapy in a Rural Paediatric Cohort in KwaZulu-Natal, South Africa. AIDS and Behavior, 2016, 20, 2729-2738.	1.4	7
81	Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 536-542.	0.9	7
82	Evaluation of a synthetic peptide for the detection of anti-Mycobacterium tuberculosis curli pili IgG antibodies in patients with pulmonary tuberculosis. Tuberculosis, 2018, 109, 80-84.	0.8	7
83	Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. Journal of Antimicrobial Chemotherapy, 2021, 76, 718-721.	1.3	7
84	Plasma Biomarkers of Risk of Tuberculosis Recurrence in HIV Co-Infected Patients From South Africa. Frontiers in Immunology, 2021, 12, 631094.	2.2	7
85	Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. BMJ Open, 2021, 11, e050116.	0.8	7
86	Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. Lancet HIV,the, 2022, 9, e130-e138.	2.1	7
87	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine, 2022, 45, 101328.	3.2	7
88	Role of Education in HIV Clinical Outcomes in a Tuberculosis Endemic Setting. Journal of the International Association of Providers of AIDS Care, 2014, 13, 402-408.	0.6	6
89	Antibiotic stewardship for drug resistant tuberculosis. Expert Opinion on Pharmacotherapy, 2016, 17, 1981-1983.	0.9	6
90	Improving survival with tuberculosis & HIV treatment integration: A mini-review. Indian Journal of Medical Research, 2019, 150, 131.	0.4	6

#	Article	IF	CITATIONS
91	HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa. Journal of Global Antimicrobial Resistance, 2022, 29, 468-475.	0.9	6
92	Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2022, 75, 1489-1496.	2.9	6
93	Sustainability of task-shifting for antiretroviral treatment. Lancet, The, 2012, 380, 1907-1908.	6.3	5
94	Adolescent antiretroviral management: Understanding the complexity of non-adherence. South African Medical Journal, 2015, 105, 953.	0.2	5
95	A clusterâ€randomized controlled trial to improve the quality of integrated HIVâ€ŧuberculosis services in primary healthcareclinics in South Africa. Journal of the International AIDS Society, 2021, 24, e25803.	1.2	5
96	Barriers to effective uptake of malaria prevention interventions in Ibadan, South West Nigeria: a qualitative study. International Journal of Community Medicine and Public Health, 2018, 5, 1304.	0.0	5
97	Tuberculosis treatment outcomes among peri-urban children receiving doorstep tuberculosis care. International Journal of Tuberculosis and Lung Disease, 2016, 20, 235-239.	0.6	4
98	Turning the tide against tuberculosis. International Journal of Infectious Diseases, 2017, 56, 6-9.	1.5	4
99	Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial. EClinicalMedicine, 2022, 44, 101298.	3.2	4
100	Recurrent Subclinical Tuberculosis Among Antiretroviral Therapy–Accessing Participants: Incidence, Clinical Course, and Outcomes. Clinical Infectious Diseases, 2022, 75, 1628-1636.	2.9	4
101	Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing. Clinical Infectious Diseases, 2020, 71, 2981-2985.	2.9	3
102	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine, 2022, 47, 101396.	3.2	3
103	Spatiotemporal Clustering of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Is Associated With Human Immunodeficiency Virus Status and Drug-Susceptibility Patterns in KwaZulu-Natal, South Africa. Clinical Infectious Diseases, 2020, 70, 2224-2227.	2.9	2
104	A Quality Improvement Intervention to Inform Scale-Up of Integrated HIV-TB Services: Lessons Learned From KwaZulu-Natal, South Africa. Global Health, Science and Practice, 2021, 9, 444-458.	0.6	2
105	Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa. AIDS Research and Therapy, 2021, 18, 74.	0.7	2
106	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine, 2022, 77, 103886.	2.7	2
107	The World Health Organization excludes Mycobacterium tuberculosis from the 2017 priority pathogens list. South African Medical Journal, 2017, 107, 466.	0.2	1
108	Organizational contextual factors that predict success of a quality improvement collaborative approach to enhance integrated HIV-tuberculosis services: a sub-study of the Scaling up TB/HIV Integration trial. Implementation Science, 2021, 16, 88.	2.5	1

#	Article	IF	CITATIONS
109	Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 233-234.	0.4	0
110	Unusual presentation of extrapulmonary tuberculosis: A case report on mammary tuberculosis. Southern African Journal of HIV Medicine, 2011, 12, 45-46.	0.3	0
111	Scaling up TB-HIV Integration in Public Health Clinics: Translating Research Findings into Practice. , 2017, , 121-134.		0